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Acute respiratory distress syndrome (ARDS) due to methadone (MTD) toxicity is a known but rather 
uncommon phenomenon. In most of the previously reported cases of MTD-related ARDS, MTD was 
ingested orally in the form of tablets in high or unknown amounts. Despite the ﬁ ndings from the available 
literature, this case report is aimed at demonstrating that even small amounts of MTD syrup can cause 
ARDS earlier than it is usually expected. We present a non-addicted MTD-overdosed patient who developed 
ARDS after ingesting a very small amount of MTD syrup. We suggest close monitoring of MTD-overdosed 
patients from at least 48 h to 72 h for possible respiratory complications such as pulmonary oedema. 
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Methadone (MTD) is a long-acting synthetic 
opioid receptor agonist with potent analgesic effects. 
It is commonly used for detoxiﬁ cation or as a substitute 
in the treatment of opium-addicted patients (1-3). The 
clinical advantages of MTD lie in its ability to suppress 
the symptoms of heroin withdrawal, which makes it 
effective in reducing mortality and morbidity rates 
among heroin abusers (4). However, it is also 
potentially toxic, especially in non-tolerant people. 
Methadone in the form of tablets, if ingested orally, 
absorbs well and produces a peak plasma concentration 
within six to twelve hours, which may last for more 
than 72 h after a single oral dose (5). It is metabolized 
in the liver with an average elimination half-life of 
25 h (6). MTD has variant isomers (S, D, and R-
isomer), but the most commonly used variation is its 
racemic type (mixture of D and S forms) (7, 8). These 
isomers have different pharmacokinetics including 
different volumes of distribution and elimination half-
lives. 
Acute respiratory distress syndrome (ARDS) is a 
known but uncommon MTD-related phenomenon that 
has already been reported in the literature (9-11). 
However, in most cases, methadone was ingested 
orally in the form of tablets in high or unknown 
amounts (12). This case report presents a non-addicted 
patient who developed ARDS after an overdose with 
MTD syrup.
CASE REPORT
A non-opioid-dependent 26-year-old woman was 
referred to our emergency department (ED) in a coma. 
The patient’s spouse had been enrolled in an opioid 
detoxiﬁ cation program that prescribed the use of MTD 
syrup. The patient had accidentally swallowed about 
10 mL of MTD syrup (containing 5 mg mL-1 of MTD) 
2 h before being admitted to hospital. On arrival, she 
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did not respond to pain stimuli and had pinpoint pupils 
and bradypnoea, but had no cyanosis or signs of 
respiratory distress. During her initial examination, her 
blood pressure was 100/75 mm Hg, pulse rate was 
74 bpm, respiratory rate was 9 breaths per minute, and 
temperature was 36.8 °C. Blood glucose levels 
(determined by bedside glucometry), electrolytes, and 
renal function tests were all within normal limits. First 
arterial blood gas (ABG) analysis showed mild 
respiratory acidosis due to hypoventilation (pH=7.29, 
PaCO2=49 mm Hg, PaO2=72 mm Hg, HCO3=23.8 mEq 
dL-1, and O2 Sat=91 %). Initial chest X-ray and 
electrocardiogram were both normal. There were no 
signs of head trauma or focal neurologic signs. Urine 
toxicology was positive for methadone. The patient 
recovered after initial supportive care including airway 
maintenance, O2 therapy (7 L min
-1 nasal), and a bolus 
dose of 1.2 mg of intravenous naloxone to reverse the 
signs and symptoms of hypoventilation. The patient 
completely regained consciousness and her respiratory 
rate increased to 18 breaths per minute. Meanwhile, 
pulse oximetry showed oxygen saturation to be 93 %. 
Three hours after admission, the patient was transferred 
to the intensive care unit (ICU) for cardiac monitoring 
and pulse-oximetry. She received a maintenance dose 
of IV naloxone (0.8 mg in 1000 mL half normal saline 
with a rate of 100 mL h-1) to prevent the recurrence of 
hypoventilation. Within the first ten hours after 
admission, she fully recovered.
About seven hours after admission to the ICU (10 h 
after admission to the ED), she began to experience 
gradual respiratory distress, sweating, mild agitation, 
and had diffuse ﬁ ne inspiratory crackles in both lungs 
at auscultation. ABG showed hypoxia (PaO2 = 
60 mm Hg) and oxygen saturation of 82 % as well as 
a Fio2/PaO2 ratio of less than 200. A chest X-ray 
revealed diffuse bilateral patchy inﬁ ltrations. Central 
vein pressure was within normal range (16 cm H2O). 
The patient was intubated and ventilated with positive 
end expiratory pressure (PEEP) of 7 cm H2O for 8 h. 
About 18 h after admission (8 h after the development 
of ARDS), she completely recovered, oxygenation 
was normalized, and she was extubated. She was 
discharged from the hospital in good condition 22 h 
after the extubation.
DISCUSSION
As MTD half-life varies between 25 h and 52 h, 
the signs and symptoms of an overdose can manifest 
late, prolonging the clinical course of the toxicity (13). 
These signs and symptoms usually occur within 6 h 
to 12 h; however, this varies depending on the MTD 
variant (14).
In the patient from this case report, the triad of 
opioid toxidrome appeared about 2 h after ingestion. 
This may suggest that the signs and symptoms of an 
overdose appear earlier in subjects who overdose on 
MTD syrup than in subjects who consume tablets. In 
a study by LoVecchio et al. (15), an acute MTD 
overdose resulted in symptoms within 9 h of ingestion 
and all of the symptoms were resolved within 24 h. 
Clark and Milory (13) showed that MTD toxicity was 
more likely in those who try the drug for the ﬁ rst time, 
before developing any tolerance. Although a deﬁ nite 
toxic dose in non-addicted people has not been set, an 
ingestion of 800 mg could be fatal (16). As little as 
40 mg to 50 mg may produce loss of consciousness 
and bradypnoea (17), while in non-tolerant adults, 
100 mg can cause life-threatening poisoning (18) due 
to respiratory arrest. 
Our patient was in a coma and had bradypnoea 
(RR<10 min-1) after ingesting 50 mg (10 mL) of MTD 
syrup, responding dramatically to a prescription of 
naloxone. This is in accordance with the results of 
studies by Zyroff et al. (19) and Garden et al. (20), 
who stated that 40 mg of MTD can lead to a coma and 
respiratory compromise in non-addicted people. No 
author has, however, speciﬁ ed the exact MTD dose 
that leads to non-cardiogenic pulmonary oedema.
In our patient, 50 mg of a mixture of MTD isomer 
D & S-form led to ARDS, an uncommon complication 
for this type of overdose reported only in a few papers 
(12, 18, 21) but involving MTD tablets. The 
pathophysiology of ARDS after an opioid overdose 
has not been clearly deﬁ ned, but the direct toxicity of 
the drug, as well as hypoxia, acidosis, and increased 
capillary permeability (pulmonary capillary leak) are 
the most probable mechanisms (20, 22). In most cases 
of MTD-related ARDS, the possible mechanism is 
hypoxia; however, in our patient, no profound or 
prolonged hypoxia existed before the development of 
ARDS. We therefore believe that the mixture of the 
D & S-form led to ARDS through direct toxicity on 
the lung parenchyma.
ARDS can affect the future course of treatment. 
Corkery et al. (2) stated that ARDS, respiratory 
depression, and aspiration pneumonia are the main 
causes of morbidity and mortality in MTD-overdosed 
patients. Several studies have shown that MTD-related 
deaths occur rather frequently in subjects undergoing 
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rehabilitation (23, 24). Among a total of 1120 deaths 
due to opioid overdose, 12.8 % were MTD-related 
and ARDS could have well had an important role (25). 
Patients suffering from ARDS experience severe 
dyspnoea accompanied by hypoxemia and exhibit 
diffuse infiltration in chest radiographs (bilateral 
alveolar ﬁ lling pattern). In our case, a pulmonary 
oedema was established about 12 hours after ingestion, 
which is in contrast to a study by Presant et al. (21), 
who found that ARDS did not develop until 24 h after 
the overdose. MTD-related ARDS often requires a 
period of invasive mechanical ventilation depending 
on its severity and fortunately, most cases are self-
limited with rapid resolution by assisted ventilation 
such as PEEP or continuous positive airway pressure 
(CPAP) (12). Ridgway and Pountney (12) reported 
that, in ARDS secondary to MTD overdoses, early 
non-invasive respiratory supportive methods such as 
bi-level positive airway pressure (BiPAP) via a 
facemask might reduce the need for invasive 
ventilation. Our patient fully recovered after 8 h of 
mechanical ventilation with PEEP (7 cm H2O), which 
is in accordance with the results of Sporer and Dorn 
(26), who stated that 33 % of MTD patients would 
need mechanical ventilation in less than 24 h. We 
successfully treated our patient with naloxone and 
applied PEEP. It should be emphasized that opiate 
antagonists such as naloxone reverse central nervous 
system and respiratory depression but do not correct 
opiate-induced pulmonary oedemas (27). This case 
also showed that MTD syrup-related ARDS (racemic 
type; a mixture of D & S forms) can occur with low 
doses of the drug, which is in contrast to previous 
claims that these complications occur after severe 
overdoses (28). MTD syrup responds to mechanical 
ventilation faster than the other preparation forms of 
this drug (e.g., MTD tablets). Although in our case 
ARDS occurred within a few hours after the 
intoxication, some authors believe that the occurrence 
of ARDS may be delayed due to recurrent respiratory 
arrest and hypoxia. They have therefore recommended 
that MTD-overdosed patients should be closely 
monitored at hospital for 72 h because of the risk of 
pulmonary oedema (28).
CONCLUSION
In general, this case is different from other MTD 
overdose cases available in the literature, because 
ARDS occurred with lower doses of MTD syrup (in 
comparison with MTD tablets). It also showed that 
ARDS occurred even after signs of toxicity had 
improved with naloxone and the patient became 
asymptomatic. Thus, we believe that opioid-naïve 
patients with acute MTD intoxication should be 
observed for at least 48 h to 72 h for possible 
occurrences of ARDS due to the prolonged elimination 
half-life of MTD.
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Sažetak
AKUTNI RESPIRATORNI DISTRES SINDROM UZROKOVAN SIRUPOM METADONA 
Akutni respiratorni distres sindrom (ARDS) uzrokovan toksičnošću metadona (MTD) poznat je ali rijedak 
fenomen. U većini dosadašnjih slučajeva ARDS-a uzrokovanog MTD-om, MTD je konzumiran u obliku 
tableta te u velikoj ili nepoznatoj količini. Unatoč nalazima dostupne literature, ovaj prikaz slučaja dokazuje 
kako čak i mala količina sirupa MTD-a može uzrokovati ARDS, i to ranije nego što bi se očekivalo. 
Obrađen je slučaj pacijentice koja nije bila ovisnica, a oboljela je od ARDS-a nakon konzumacije tek male 
količine sirupa MTD-a. Predlažemo pomnije praćenje pacijenata predoziranih MTD-om od najmanje 48 
sati do 72 sata usmjereno na detekciju respiratornih komplikacija poput plućnih edema. 
KLJUČNE RIJEČI: plućni edem, predoziranje, respiratorne komplikacije, slučajna intoksikacija
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